Stock Forecast

  Constellation Pharmaceuticals, Inc. ( CNST) Stock. Should you Buy or Sell?    $ 33.99

0.00 (0.00 %)

Constellation Pharmaceuticals, Inc. Analysis

Updated on 10-09-2022
Symbol CNST
Price $33.99
Beta 2.580
Volume Avg. $1.57 M
Market Cap $1.63 B
52 Week Range $17.0 - $39.3

Constellation Pharmaceuticals, Inc. opened the day at $33.99 which is 0.00 % on yesterday's close. Constellation Pharmaceuticals, Inc. has a 52 week high of $39.3 and 52 week low of $17.0, which is a difference of $22.3. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.63 B and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Constellation Pharmaceuticals, Inc. for $1.63 B, it would take 15 years to get your money back. Constellation Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Constellation Pharmaceuticals, Inc. Stock Forecast - Is Constellation Pharmaceuticals, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value

PE Ratio -11.533
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing Constellation Pharmaceuticals, Inc.

Price Book Value Ratio 4.309 Price To Book Ratio 4.309
Price To Sales Ratio 0.000 Price Earnings Ratio -11.533

How liquid is Constellation Pharmaceuticals, Inc.

Current Ratio 15.389
Quick Ratio 15.078


Debt Ratio 0.063 Debt Equity Ratio 0.067
Long Term Debt To Capitalization 0.000 Total Debt To Capitalization 0.000

Latest news about Constellation Pharmaceuticals, Inc.

MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology

Company Announces Successful Completion of Tender Offer   Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest and subject to any applicable withholding of taxes. The tender offer expired at one minute after 11:59 p.m.

Date : 15/07/2021

Constellation Pharmaceuticals Provides an Update from the Ongoing MANIFEST Study of Pelabresib

CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting. The data in these posters are based on a data cutoff of September 29, 2020 from the MANIFEST Phase 2 clinical trial and reflect an analysis of pelabresib clinical and translational activity.

Date : 11/06/2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNST

NEW YORK, June 4, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Constellation Pharmaceuticals, Inc. ("CNST" or the "Company") ( CNST ) relating to its proposed acquisition by MorphoSys AG (MOR). Under the terms of the agreement, CNST shareholders will receive $34.00 in cash per share they own.

Date : 04/06/2021

Why Constellation Pharmaceuticals Stock Was Crushing It This Week

The small drugmaker is being acquired by MorphoSys.

Date : 03/06/2021

SHAREHOLDER ALERT: WeissLaw LLP Investigates Constellation Pharmaceuticals, Inc.

NEW YORK, June 2, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Constellation Pharmaceuticals, Inc. ("Constellation" or the "Company") (NASDAQ: CNST) in connection with the proposed acquisition of the Company by MorphoSys AG ("MorphoSys") (FSE: MOR; NASDAQ: MOR). The transaction is structured as an all-cash tender offer pursuant to which the Company's shareholders will receive $34.00 for each share of Constellation common stock that they hold.

Date : 02/06/2021

About Constellation Pharmaceuticals, Inc.

CEO : Mr. Jigar Raythatha
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : Nasdaq Global Select

Description :

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

My Newsletter

Sign Up For Updates & Newsletters